Photo from ESTRO/X
Jul 25, 2024, 08:21
5-year results of the hypo-FLAME trial on focal boost SBRT for prostate cancer – ESTRO
European Society for Radiotherapy and Oncology (ESTRO) shared a post on X:
“5-year results of the hypo-FLAME trial on focal boost SBRT for intermediate/high-risk prostate cancer. Presented at ESTRO24, it shows excellent biochemical disease-free survival (93%) and low toxicity with a 5-fraction SBRT schedule.”
Read further.
Source: ESTRO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 10:19
Dec 21, 2024, 09:22
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29